NASDAQ:ACER

Acer Therapeutics Stock Forecast, Price & News

$2.41
+0.06 (+2.55 %)
(As of 08/5/2021 12:03 PM ET)
Add
Compare
Today's Range
$2.39
$2.41
50-Day Range
$2.30
$3.10
52-Week Range
$2.15
$5.84
Volume1,528 shs
Average Volume543,964 shs
Market Capitalization$34.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51
30 days | 90 days | 365 days | Advanced Chart
Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for Acer Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Acer Therapeutics logo

About Acer Therapeutics

Acer Therapeutics, Inc. is a pharmaceutical company. It engages in the acquisition, development and commercialization of therapies for medical needs. Its product pipeline includes ACER-001 Edsivo and ACER-2820. The Edsivo is a type of celiprolol for Vascular Ehlers-Danlos syndrome. The ACER-001 is for the treatment of urea cycle disorders and Maple Syrup Urine diseases. The company was founded on March 15, 1991 and is headquartered in Newton, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.10 out of 5 stars

Medical Sector

1152nd out of 1,311 stocks

Pharmaceutical Preparations Industry

571st out of 647 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

Is Acer Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Acer Therapeutics stock.
View analyst ratings for Acer Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Acer Therapeutics?

Wall Street analysts have given Acer Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Acer Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Acer Therapeutics
.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) announced its quarterly earnings data on Sunday, May, 16th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.44) by $0.33. The biopharmaceutical company earned $4 million during the quarter, compared to analyst estimates of $2 million.
View Acer Therapeutics' earnings history
.

How has Acer Therapeutics' stock been impacted by Coronavirus?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ACER shares have decreased by 28.7% and is now trading at $2.41.
View which stocks have been most impacted by COVID-19
.

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Christopher Schelling, President, Chief Executive Officer & Director
  • Harry S. Palmin, Chief Operating & Financial Officer
  • Stacey Bain, Vice President-Clinical Operations
  • John M. Klopp, Chief Technology Officer
  • Matthew T. Seibt, Chief Commercial Officer

What is Jason Chen's approval rating as Acer Therapeutics' CEO?

64 employees have rated Acer Therapeutics CEO Jason Chen on Glassdoor.com. Jason Chen has an approval rating of 99% among Acer Therapeutics' employees. This puts Jason Chen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Novavax (NVAX), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Sarepta Therapeutics (SRPT), Advanced Micro Devices (AMD), Amarin (AMRN), VBI Vaccines (VBIV), NVIDIA (NVDA), Idera Pharmaceuticals (IDRA) and Inovio Pharmaceuticals (INO).

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $2.41.

How much money does Acer Therapeutics make?

Acer Therapeutics has a market capitalization of $34.49 million. The biopharmaceutical company earns $-22,890,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis.

How many employees does Acer Therapeutics have?

Acer Therapeutics employs 21 workers across the globe.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is www.acertx.com.

Where are Acer Therapeutics' headquarters?

Acer Therapeutics is headquartered at 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at (844) 902-6100 or via email at [email protected]


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.